Melanoma News and Research

Latest Melanoma News and Research

Experts help raise awareness about dangers of melanoma in the U.S.

San Diego is one of the top 10 sunniest cities in the United States. Even when "June Gloom" clouds our skies, the sun is still very powerful. With that in mind, experts with UC San Diego Moores Cancer Center are helping raise awareness of the dangers of melanoma, the most serious type of skin cancer.

21 Jun 2011

IsoRay announces combination therapy study for prostate cancer

IsoRay Inc., announced today a new dual therapy study using Cesium-131 brachytherapy (internal radiation therapy) and external beam radiation. Multiple sites have now received Institutional Review Board (IRB) approval for this study which will examine the efficacy of combining intensity modulated radiation (IMRT) with Cesium-131 brachytherapy to treat intermediate and high risk early stage prostate cancer.

20 Jun 2011

Novel vaccine approach for prostate cancer

Mayo Clinic investigators and collaborators from the United Kingdom cured well-established prostate tumors in mice using a human vaccine with no apparent side effects. This novel cancer treatment approach encourages the immune system to rid itself of prostate tumors without assistance from toxic chemotherapies and radiation treatments.

20 Jun 2011

FDA approves NULOJIX

Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) approved NULOJIX, the first selective T-cell costimulation blocker indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant, in combination with basiliximab induction, mycophenolate mofetil (MMF), and corticosteroids.

18 Jun 2011

Adaptimmune melanoma trial opening

Adaptimmune announced today that it has opened a Phase I/II, two cohort, open label clinical trial in metastatic melanoma at Washington University, St. Louis, Missouri.

16 Jun 2011

Cancer Research UK to launch genetic testing programme

Cancer Research UK's chief executive Harpal Kumar today spoke of a 'golden era' for cancer research as the UK is poised to lead the world in individualising the practice of medicine by understanding which treatments are best suited to an individual patient's particular genetic type of cancer.

16 Jun 2011

Provectus PV-10 Phase 2 trial data on metastatic melanoma to be presented at two conferences

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at two upcoming melanoma conferences.

16 Jun 2011

Galectin strengthens cancer drug patent portfolio in Europe

Galectin Therapeutics Inc. today announced that the European Patent Office has granted the Company a new patent, No. 02731178.6, "Co-administration of a Polysaccharide with a Chemotherapy for the Treatment of Cancer".

15 Jun 2011

OncoSec Medical third quarter net loss increases to $491,000

OncoSec Medical Incorporated, which is developing its advanced-stage ElectroOncology therapies to treat solid tumor cancers, today reported financial results for the quarter ended April 30, 2011.

15 Jun 2011

Wnt signaling may help target hair pigmentation

A new study by researchers at NYU Langone Medical Center has shown that, for the first time, Wnt signaling, already known to control many biological processes, between hair follicles and melanocyte stem cells can dictate hair pigmentation. The study was published in the June 11, 2011 issue of the journal Cell.

15 Jun 2011

FDA's new sunscreen regulations will help reduce skin cancer risk

The American Academy of Dermatology Association (Academy) today said that the U.S. Food and Drug Administration's (FDA) new sunscreen regulations will help Americans reduce their risk for skin cancer by guiding them to the most effective sunscreens and advising them on other sun-protection measures.

15 Jun 2011

New FDA rules for sunscreen labels

The U.S. Food and Drug Administration this Tuesday released new rules that specify sunscreens’ labeling. The rules specify which lotions protect the skin and which do not.

15 Jun 2011

Flip-flops and baseball caps could pose a hidden health risk from skin cancer

Cheap, convenient and casual, baseball caps and flip-flops have a trendy charm. Those qualities make them must-wear accessories for teens, outdoor enthusiasts, gardeners or anyone trying to keep cool during the sweltering days of summer.

15 Jun 2011

FDA approves Cornell Dots for first-in-human clinical trial for treatment of cancer

The U.S. Food and Drug Administration (FDA) has approved the first clinical trial in humans of a new technology: Cornell Dots, brightly glowing nanoparticles that can light up cancer cells in PET-optical imaging.

14 Jun 2011

UC Davis, Jackson Laboratory and NCI partner for human clinical trials on cancer

About nine out of 10 new cancer drugs successfully clear preclinical development hurdles, but then they fail in human clinical testing. A new partnership facilitated by SAIC-Frederick Inc. aims to help change that outcome.

13 Jun 2011

Scientists pioneer way to find more chromosomal aberrations in tumors

Washington University Pediatric Cancer Genome Project scientists pioneer way to find more chromosomal aberrations in tumors; results likely to advance understanding of cancer.

13 Jun 2011

CDA attempts to clear confusion over vitamin D and sun exposure

The debate about vitamin D and sun exposure has been ongoing and the Canadian Dermatology Association (CDA) hopes to clear up some of the confusion.

10 Jun 2011

Surgeon uses radiotracers to detect the ganglion through which tumour attempts to spread

Dr Naia Uribe-Etxebarria has shown that it is viable to detect the ganglion through which a tumour attempts to spread, using a radiotracer, in a PhD defended at the University of the Basque Country.

10 Jun 2011

FDA accepts ZIOPHARM's IND for ZIN ATI-001 to treat melanoma

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today that the U.S. Food & Drug Administration has accepted the Company's investigational new drug application to begin clinical study of ZIN ATI-001, a novel DNA-based therapeutic candidate also known as Ad-RTS-IL-12 + AL, in oncology.

10 Jun 2011

Scientists uncover new role for key cancer protein

Scientists at Dana-Farber Cancer Institute have uncovered a new role for a key cancer protein, a finding that could pave the way for more-effective radiation treatment of a variety of tumors.

10 Jun 2011